Article contents
Surrogate Endpoints and Drug Regulation: What Is Needed to Clarify the Evidence
Published online by Cambridge University Press: 01 January 2021
Abstract
The FDA's new table of surrogate endpoints used for drug approvals is an important step forward for overseeing the use of biomarkers in clinical trials. Nevertheless, we present several ways in which the table can be improved.
- Type
- Symposium Articles
- Information
- Journal of Law, Medicine & Ethics , Volume 47 , Issue 3: Biomarker Research and Validation: Current Challenges, Future Opportunities , Fall 2019 , pp. 381 - 387
- Copyright
- Copyright © American Society of Law, Medicine and Ethics 2019
References
- 2
- Cited by